DC vaccinations for colorectal cancer primed with carcinoembryonic antigen (CEA) peptide and mRNA have been reported to induce CEA-specific CTLs exhibiting disease stability and response in a proportion of patients [12,13,14,15,16,17]. The gene discussed is CEACAM5; the disease is colorectal cancer.